Drug
Fruquintinib Sintilimab
Fruquintinib Sintilimab: highest development phase Phase 2/3, developed by Hutchmed. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Hutchmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| fruquintinib+sintilimab NCT05522231 | Phase 2/3 | Advanced Renal Cell Carcinoma |
Latest
No recent events.
Follow Fruquintinib Sintilimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.